Director Camilla V. Simpson awarded 1,700 SPRB options at $52.70 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SIMPSON CAMILLA V

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,700	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,700 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 1,700 shares Exercise price: $52.70 per share Option expiration: May 20, 2036 +2 more

5 metrics

Options granted 1,700 shares Stock Option (Right to Buy) grant to director

Exercise price $52.70 per share Conversion or exercise price of stock options

Option expiration May 20, 2036 Expiration date of the granted stock options

Shares following transaction 1,700 options Total derivative shares held after this grant

Vesting reference year 2027 annual meeting Latest date by which options will be fully vested

Key Terms

Stock Option (Right to Buy), 2020 Equity Incentive Plan, Continuous Service, Change in Control

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2020 Equity Incentive Plan financial

"as defined in the 2020 Equity Incentive Plan (the "Plan")"

Continuous Service financial

"subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan"

Change in Control financial

"will vest in full upon a Change in Control (as defined in the Plan)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIMPSON CAMILLA V

(Last)

(First)

(Middle)

C/O SPRUCE BIOSCIENCES, INC.

611 GATEWAY BOULEVARD, SUITE 740

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$52.7	05/21/2026		A		1,700		⁽¹⁾	05/20/2036	Common Stock	1,700	$0	1,700	D

Explanation of Responses:

1. The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

	/s/ Samir Gharib, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did SPRUCE BIOSCIENCES (SPRB) report for Camilla V. Simpson?

Spruce Biosciences reported a grant of stock options to director Camilla V. Simpson for 1,700 underlying common shares. This is a compensation-related award, not an open-market purchase or sale, and was recorded as an acquisition of derivative securities.

What is the exercise price and term of Camilla V. Simpson’s SPRB stock options?

The granted stock options have an exercise price of $52.70 per share and expire on May 20, 2036. This long-dated term gives the director many years during which she may choose to exercise the options if conditions are favorable.

How do Camilla V. Simpson’s SPRB stock options vest under this Form 4?

The options generally vest on the first anniversary of the grant date, but will in any case be fully vested by the company’s 2027 annual stockholder meeting. Vesting is conditioned on continuous service and accelerates to full vesting upon a Change in Control as defined in the plan.

How many SPRB shares are covered by Camilla V. Simpson’s new stock option award?

The stock option award covers 1,700 shares of Spruce Biosciences common stock. Following this grant, her reported derivative holdings in this option series total 1,700 shares, reflecting the full amount of the new compensation-related award recorded in the Form 4.

Is Camilla V. Simpson’s SPRB Form 4 a buy or sell transaction?

The Form 4 reflects an acquisition of derivative securities through a grant, coded as an “A” transaction. It is a grant or award of stock options, not an open-market buy or sell of Spruce Biosciences common shares by the director.